Yoshiyuki Tsujihata

Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist

Nobuyuki Negoro, Shinobu Sasaki, Satoshi Mikami et al. · ACS Medicinal Chemistry Letters · 2010 · 246 citations · Full text

Molecular Pharmacology, Pharmaceutical Science, Selective Gpr40 Agonist +12

Visualizing and Modulating Mitophagy for Therapeutic Studies of Neurodegeneration

Hiroyuki Katayama, Hiroshi Hama, Koji Nagasawa et al. · Cell · 2020 · 164 citations · Full text

Cell Autophagy, Mitophagy, Neurodegenerative Diseases +9

TAK-875, an Orally Available G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1 Agonist, Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats

Yoshiyuki Tsujihata, Ryo Ito, Masami Suzuki et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 145 citations

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

Chiori Yabuki, Hidetoshi Komatsu, Yoshiyuki Tsujihata et al. · PLoS ONE · 2013 · 91 citations · Full text

Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists

Shinobu Sasaki, Shuji Kitamura, Nobuyuki Negoro et al. · Journal of Medicinal Chemistry · 2011 · 87 citations · Full text

Gpr40 Agonist Activity, Insulin Signaling, Metabolic Syndrome +16